TL;DR

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that BPC-157, TB-500, KPV, and MOTS-c be added to the Section 503A Bulks List — the list that would make it clear compounding pharmacies can legally prepare them for patients. The committee’s vote on BPC-157 and KPV was 8-6, with one abstention. That’s notable because it goes against FDA staff’s own briefing materials, which had recommended against adding any of the seven peptides under review. The vote is advisory only — the FDA itself still has to decide whether to act on it. On day two (July 24) the committee also recommended Semax (8-5) and Epitalon (7-4), and declined to recommend DSIP/emideltide (6-7). Final tally: 6 of 7 peptides recommended.

Update, October 1, 2026: the FDA has not yet published a proposed rule adding any of these peptides to the 503A Bulks List (as of mid-September 2026). Rulemaking could take into 2027 or longer. We will update this page and the legal status tracker when it moves.

The distinction people get wrong

A PCAC “yes” vote is not a legalization. It’s a recommendation from outside experts to FDA staff, who retain full discretion over whether to actually amend the 503A Bulks List through formal rulemaking. Even if FDA follows the recommendation, being added to that list only means a compounding pharmacy filling a valid prescription may legally prepare the peptide — it still would not be an FDA-approved drug, and it would still require a prescription from a licensed provider. None of this changes the legal status of the unregulated “research chemical” products sold online, which remain outside any legitimate medical supply chain regardless of what the committee decided.

The dated timeline

• Apr 15, 2026 — FDA formally removes 12 peptides, including BPC-157, TB-500, KPV, and MOTS-c, from its Category 2 (restricted) compounding list.
• Jul 23, 2026 (Day 1) — PCAC reviews BPC-157, KPV, TB-500, and MOTS-c for 503A Bulks List eligibility. FDA’s own briefing documents recommend against adding any of them, citing limited human safety and effectiveness data. The committee votes 8-6, with one abstention, in favor of BPC-157 and KPV; TB-500 and MOTS-c are also recommended by the panel. Committee members who voted yes generally judged the safety risk to be low; those who voted no cited thin human data and concern that compounding-list inclusion would be read as an FDA safety endorsement it isn’t.
• Jul 24, 2026 (Day 2) — PCAC recommends Semax (8-5, 1 abstention) and Epitalon (7-4, 1 abstention). DSIP/emideltide is not recommended (6-7, 1 abstention). MOTS-c’s Day 1 vote was 7-5 with 2 abstentions; TB-500’s was 8-6 with 1 abstention.
• As of mid-Sep 2026 — No proposed rule published yet.
• Next — FDA reviews the committee’s recommendations and decides whether to initiate formal rulemaking to amend the 503A Bulks List. There is no fixed deadline for that decision, and FDA is not obligated to follow the vote.

What this means for you

Nothing changes today for how you can legally obtain any of these peptides. If FDA eventually adopts the committee’s recommendation, the practical effect would be that a licensed provider could write a prescription for BPC-157, TB-500, KPV, or MOTS-c and a compounding pharmacy could legally fill it — closing off the gray-market argument that “there’s no legal way to get this.” Until and unless that rulemaking happens, the legitimate path is unchanged: a conversation with a licensed provider about whether any of this is appropriate for you, not a purchase from a vendor selling “research chemicals.” For the current status of every peptide under review, see the live legal status tracker, and for the full backstory on how the meeting was set up, see PCAC July 2026 Review Explained.

Sources

• McDermott Will & Schulte — “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting”

• AJMC — “FDA Panel Backs 6 Peptides for Compounding”

• STAT News — “FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr.”

• NPR — “Advisers to the FDA vote to ease regulation of popular peptides”

• ABC News — “FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list”

• The Hill — “FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists”

• FDA — July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee

This article is educational and is not legal or medical advice. Regulatory status changes fast — check the tracker for the current picture and talk to a licensed provider before making any decision.

← All articles